The inhibition of MLK3 activity with the MLK3 inhibitor CEP1347 resulted in a significant increase in cell populations in the G2/M phase in ovarian cancer cells, which could also lead to G2/M arrest in breast cancer cells [70]. This evidence concerns the gene MAP3K11 and ovarian cancer.